European Commission Approves Novartis’ Cosentyx for PMR
The European Commission approved Novartis’ Cosentyx for polymyalgia rheumatica.
Story updates
03:04:01 PM UTC
SquawkNews
Novartis received European Commission approval for Cosentyx (secukinumab) to treat adults with polymyalgia rheumatica who inadequately respond to glucocorticoids or relapse during taper.Material DetailsContext by AI AnalystThis is a mid-cycle lifecycle expansion for Cosentyx, extending its autoimmu…